Jnana Therapeutics to Present Preclinical Data on its PKU Program at the 2023 Society for Inherited Metabolic Disorders Annual Meeting
Jnana Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Jan. 6, 2023 /PRNewswire/ -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for the clinical study of JNT-517 for the treatment of phenylketonuria (PKU).
BOSTON, Jan. 5, 2023 /PRNewswire/ -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 3:30 p.m. PT (6:30 p.m. ET).
Jnana Therapeutics is deepening its ties with Roche, revealing Tuesday its second deal with the Swiss pharmaceutical giant since 2020 alongside a fresh round of funding.
Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform
Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for highly validated,...
BOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to address well-validated but hard-to-drug targets, today announced that it has selected JNT-517 as a development candidate and a potential first-in-class oral approach for the treatment of phenylketonuria (PKU), a rare inherited metabolic disease. The company also announced plans to initiate a Phase 1 clinical study with JNT-517 later this year.
BOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target well-validated but hard-to-drug targets, today announced the appointment of John Throup, Ph.D. as Senior Vice President, Head of Development.
After years chasing a hard-to-drug group of targets called solute carriers, Jnana Therapeutics is revealing its lead program and a new $50 million financing to get it into the clinic.